LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2130 ◽

2021 ◽

Vol 32 ◽

pp. S1328

Author(s):

M. Gogishvili ◽

T. Melkadze ◽

T. Makharadze ◽

D. Giorgadze ◽

M. Dvorkin ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.10.022 ◽

2021 ◽

Vol 16 (1) ◽

pp. S2

Author(s):

M. Reck ◽

T.-E. Ciuleanu ◽

M.C. Dols ◽

M. Schenker ◽

B. Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non–Small-Cell Lung Cancer in the First-Line Setting?

Journal of Clinical Oncology ◽

10.1200/jco.19.02509 ◽

2020 ◽

Vol 38 (8) ◽

pp. 843-844 ◽

Cited By ~ 1

Author(s):

Tomohiro Tanaka ◽

Hiroto Ishiki ◽

Emi Kubo ◽

Sayuri Yokota ◽

Masaki Shimizu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Line Setting ◽

Egfr Mutated ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

Annals of Oncology ◽

10.1093/annonc/mdz453.004 ◽

2019 ◽

Vol 30 ◽

pp. xi67-xi68 ◽

Cited By ~ 8

Author(s):

L. Paz-Ares ◽

T.E. Ciuleanu ◽

X. Yu ◽

P. Salman ◽

A. Pluzanski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Final Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.10.023 ◽

2021 ◽

Vol 16 (1) ◽

pp. S2-S3

Author(s):

S.S. Ramalingam ◽

T.E. Ciuleanu ◽

A. Pluzanski ◽

J.-S. Lee ◽

M. Schenker ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.9001 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 9001-9001 ◽

Cited By ~ 59

Author(s):

Hossein Borghaei ◽

Matthew David Hellmann ◽

Luis G. Paz-Ares ◽

Suresh S. Ramalingam ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

Annals of Oncology ◽

10.1093/annonc/mdz394.075 ◽

2019 ◽

Vol 30 ◽

pp. v913-v914 ◽

Cited By ~ 12

Author(s):

S. Peters ◽

S.S. Ramalingam ◽

L. Paz-Ares ◽

R. Bernabe Caro ◽

B. Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Low Dose ◽

Final Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data

Annals of Oncology ◽

10.1016/j.annonc.2021.03.195 ◽

2021 ◽

Vol 32 (5) ◽

pp. 687-688

Author(s):

S. Peters ◽

U. Dafni ◽

M. Perol ◽

E. Felip ◽

L. Polito ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Real World ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Real World Data ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.111 ◽

2021 ◽

Vol 32 ◽

pp. S1414

Author(s):

T. Makharadze ◽

R.G. Quek ◽

T. Melkadze ◽

M. Gogishvili ◽

C. Ivanescu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Patient Reported ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

10.1158/1538-7445.am2018-ct077 ◽

2018 ◽

Cited By ~ 2

Author(s):

Matthew D. Hellmann ◽

Tudor Eliade Ciuleanu ◽

Adam Pluzanski ◽

Jong Seok Lee ◽

Gregory Otterson ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Initial Results ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.9020 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 9020-9020 ◽

Cited By ~ 4

Author(s):

Martin Reck ◽

Matthew David Hellmann ◽

Luis G. Paz-Ares ◽

Suresh S. Ramalingam ◽

Julie R. Brahmer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Patient Reported ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text